ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Revenue per Share : HK$0.00 (TTM As of Dec. 2023)

ImmuneOnco Biopharmaceuticals (Shanghai) Revenue per Share Chart

Competitive Comparison of ImmuneOnco Biopharmaceuticals (Shanghai)'s Revenue per Share

For the Biotechnology subindustry, ImmuneOnco Biopharmaceuticals (Shanghai)'s PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ImmuneOnco Biopharmaceuticals (Shanghai)'s PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmuneOnco Biopharmaceuticals (Shanghai)'s PS Ratio distribution charts can be found below:

* The bar in red indicates where ImmuneOnco Biopharmaceuticals (Shanghai)'s PS Ratio falls into.

ImmuneOnco Biopharmaceuticals (Shanghai) Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

ImmuneOnco Biopharmaceuticals (Shanghai)'s Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as

ImmuneOnco Biopharmaceuticals (Shanghai)'s Revenue Per Share for the quarter that ended in Dec. 2023 is calculated as

Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImmuneOnco Biopharmaceuticals (Shanghai)  (HKSE:01541) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

ImmuneOnco Biopharmaceuticals (Shanghai) Revenue per Share Related Terms

Thank you for viewing the detailed overview of ImmuneOnco Biopharmaceuticals (Shanghai)'s Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Business Description